|Datasheet||Specific References||Reviews||Related Products||Protocols|
The pGEM-T is 3kb in length, and contains the amplicin resistance gene, conferring selection of the plasmid in E. coli, and the ori site which is the bacterial origin of replication. The plasmid has multiple cloning sites as shown below. The coding sequence was inserted by TA cloning. Many E. coli strains are suitable for the propagation of this vector including JM109, DH5α and TOP10.
The coding sequence can be easily obtained by digesting the vector with proper restriction enzyme(s). The coding sequence can also be amplified by PCR with M13 primers, or primer pair SP6 and T7.
|Cynomolgus monkey EPO Gene cDNA Clone (full-length ORF Clone), expression ready, FLAG-tagged||CG90133-G-F|
|Cynomolgus monkey EPO Gene cDNA Clone (full-length ORF Clone), expression ready, His-tagged||CG90133-G-H|
|Cynomolgus monkey EPO Gene cDNA Clone (full-length ORF Clone), expression ready, Myc-tagged||CG90133-G-M|
|Cynomolgus monkey EPO Gene cDNA Clone (full-length ORF Clone), expression ready, untagged||CG90133-G-N|
|Cynomolgus monkey EPO Gene cDNA Clone (full-length ORF Clone), expression ready, HA-tagged||CG90133-G-Y|
Erythropoietin is a member of the EPO / TPO family. It is a secreted, glycosylated cytokine composed of four alpha helical bundles. Erythropoietin can be found in the plasma and regulates red cell production by promoting erythroid differentiation and initiating hemoglobin synthesis. It also has neuroprotective activity against a variety of potential brain injuries and antiapoptotic functions in several tissue types. Erythropoietin is the principal hormone involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass. It is produced by kidney or liver of adult mammals and by liver of fetal or neonatal mammals. Genetic variation in erythropoietin is associated with susceptbility to microvascular complications of diabetes type 2. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. It has a longer circulating half-life in vivo. It is available under the name Aranesp (Amgen). Erythropoietin is being much misused as a performance-enhancing drug in endurance athletes.